Summit Therapeutics Inc.

Companies

Summit Therapeutics Inc [SMMT] Revenue clocked in at $0.00 million, up 80.08% YTD: What’s Next?

Summit Therapeutics Inc [NASDAQ: SMMT] price surged by 19.59 percent to reach at $0.77. The one-year SMMT stock forecast points to a potential upside of 41.25. The average equity rating for SMMT stock is currently 1.00, trading closer to a bullish pattern in the stock

Industry

Summit Therapeutics Inc [SMMT] Revenue clocked in at $0.00 million, up 69.73% YTD: What’s Next?

Summit Therapeutics Inc [NASDAQ: SMMT] price surged by 8.31 percent to reach at $0.34. The company report on January 8, 2024 at 9:00 AM that Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference. Phase II 24-Month OS

Summit Therapeutics Inc.

Summit Therapeutics Inc [SMMT] Revenue clocked in at $0.00 million, up 80.08% YTD: What’s Next?

Summit Therapeutics Inc [SMMT] Revenue clocked in at $0.00 million, up 69.73% YTD: What’s Next?

Quick Links

Categories

Get The Best Stocks To Trade Every Day!